Please assess the completion status of the following clinical trial:

Trial Title: Bryophyllum Pinnatum Treatment of Anxiety Related to Signs of Preterm Birth

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years old~* Hospitalisation with signs of preterm birth~* Gestational age at randomisation \>22 weeks (22+0) and \<35 weeks (34+6)~* Good German or English skills~* Written informed consent~Exclusion Criteria:~* Early premature rupture of the membranes (PPROM)~* Factors that make soon delivery likely (pre-eclampsia, suspect cardiotocography, clinical signs of an amniotic infection)~* Body temperature \>38°C~* Cervical opening or cervical length \< 5 mm~* Contraindication for B. pinnatum, lactose or wheat protein allergy~* Taking Bryophyllum 50% chewable tablets or powder 48 h before study inclusion~* Taking psychotropic drugs (Benzodiazepines, antidepressants, neuroleptics)~* Diagnosed psychiatric disease (depression, anxiety disorder, adaptation disorder, post- traumatic stress disorder, bipolar disorder)~* Active participation in another interventional study during the last 4 weeks~* Known or suspected non-compliance with study protocol~* Drug or alcohol abuse

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bryophyllum 50% (Type: ACTIVE_COMPARATOR): Participants of the verum group take Bryophyllum 50% chewable tablets starting the day after study inclusion. Participants take 2 tablets, four times a day for 2 weeks. If the birth takes place before the end of the 2 weeks, the study participation is terminated early.
- Placebo (Type: PLACEBO_COMPARATOR): Participants of the control group take Placebo chewable tablets starting the day after study inclusion. Participants take 2 tablets, four times a day for 2 weeks. If the birth takes place before the end of the 2 weeks, the study participation is terminated early.

Based on this trial design, predict the completion outcome and termination type (if applicable).